Genetic and Epigenetic Factors Affecting Cytochrome P450 Phenotype and Their Clinical Relevance by Tamási, Viola & Falus, András
Selection of our books indexed in the Book Citation Index 
in Web of Science™ Core Collection (BKCI)
Interested in publishing with us? 
Contact book.department@intechopen.com
Numbers displayed above are based on latest data collected. 
For more information visit www.intechopen.com
Open access books available
Countries delivered to Contributors from top 500 universities
International  authors and editors
Our authors are among the
most cited scientists
Downloads
We are IntechOpen,
the world’s leading publisher of
Open Access books
Built by scientists, for scientists
12.2%
122,000 135M
TOP 1%154
4,800
4 
Genetic and Epigenetic Factors 
Affecting Cytochrome P450 Phenotype 
and Their Clinical Relevance  
Viola Tamási and András Falus  
Semmelweis University,  
Hungary   
1. Introduction  
Pharmacogenetics (or pharmacogenomics) studies the role of inherited and acquired genetic 
variation in drug response. Clinically relevant pharmacogenetic examples, mainly involving 
drug metabolism are known for decades, but the field was not evolved until the 1970s, when 
the discovery of the CYP2D6 polymorphism and its resultant effect on drug toxicity and 
response led to many observations of pharmacogenetic-based variations in 
pharmacokinetics. These and other discoveries and the subsequent ability to genotype led to 
the term pharmacogenetics. Today, as a consequence of sequencing and mapping of the 
human genome, pharmacogenetics is becoming the first drug discovery pipeline technology 
to affect the structure and economics of the pharmaceutical industry (Daly, 2010). During 
drug development, it is important to consider pharmacogenetic variation which could 
explain or even prevent discarding a drug candidate if appropriate genetic reasons are 
identified or when lack of response/occurrence of ADRs (adverse drug reactions) in drug 
therapy is experienced. Genetic variation is taken strongly into consideration also in clinic 
during individualized therapies. It helps to improve the number of responders and decrease 
the number of patients suffering from ADRs.  
Beside genetic polymorphism there are other heritable phenotypic changes which play role 
in drug response that do not involve any alteration in nuclear DNA sequence, but affect 
gene transcription through DNA methylation, histone modification, miRNA regulation 
(called pharmacoepigenetic changes) (Berger et al., 2009). There are also non-heritable 
changes, which affect response to drugs, such as reactions to the environment, to drug-drug 
interactions through regulatory mechanisms (Tamási et al., 2003). Although fast, non-
heritable responses, which alter signal transduction pathways affect the therapeutic 
outcome of a drug tremendously, pharmacogenetic and pharmacoepigenetic difference has 
to be taken also strictly into consideration in clinical practice.  
In general one can envision important pharmacogenetic and pharmacoepigenetic variation 
1. in genes responsible for pharmacokinetic properties of the drug (genes influencing 
absorption, distribution metabolism, elimination) or 
2. in genes responsible for pharmacodinamic properties of the drug (genes affecting the 
pharmacologic effect of a drug) (Daly, 2010). 
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So far, it is apparent that heritable changes in genes encoding drug metabolizing enzymes 
often affects outcome in drug treatment to a high degree and the variability of the phase I 
enzymes plays major role in this respect, as evidenced by many studies (Spear et al., 2001; 
Ingelman-Sundberg, 2004a; Weinshilboum, 2003). In general it can be estimated that 20-25% of 
all drug therapies are influenced by such polymorphism to an extent that therapy outcome is 
changed. There are much fewer examples where the pharmacodinamic properties are 
influenced and it has clinical relevance (Ingelman-Sundberg, 2004b; Eichelbaum et al., 2006).  
In this book chapter the polymorphic and epigenetic nature of phase I enzymes will be 
discussed and their role in therapy and clinic will be highlighted. 
2. Pharmacogenetics  
All genes encoding cytochrome P450 enzymes (CYPs) in families 1–3 are polymorphic. 
However, the functional importance of the variant alleles is not the same and the frequency 
of their distribution in different ethnic groups also differs. Polymorphisms of CYPs consist 
of single nucleotide polymorphisms (SNP), gene deletions, missense mutations, insertions, 
gene duplications and deleterious mutations creating inactive gene products. Furthermore 
amino acid changes might be introduced, which changes the substrate specificity of the 
enzyme. Mutations in intronic regions could also have relevance. An important aspect of 
drug metabolizing gene polymorphism would be copy number variation (CNV) where 
multiple functional gene copies of one allele can result in increased drug metabolism and 
absence of drug response at ordinary dosage. To order and standardize allelic variants, the 
CYP-allele nomenclature committee manages the naming and definition of CYP alleles, 
which are presented on an associated web site (http://www.cypalleles.ki.se). The homepage 
contains updated information regarding the nomenclature and properties of the variant 
alleles with links to the dbSNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/) 
and relevant literature references. Based on the phenotype variability among drug 
metabolizers, the populations could be classified into four major groups: 
1. the ultrarapid metabolizers (UM); with very high drug metabolizing capacity; usually 
caring more than two active gene copies 
2. the extensive metabolizers (EM); with high drug metabolizing capacity; usually caring 
two active gene copies 
3. the intermediate metabolizers (IM); with intermediate drug metabolizing capacity; 
usually carrying one functional and one defective allel, but may also carry two partially 
defective alleles 
4. the poor metabolizers (PM); with slow, poor drug metabolizing capacity; usually 
lacking functional enzyme due to defective or deleted genes (Ingelman-Sundberg et al., 
2007). 
Taking CYP2D6-dependent metabolism as an example, the rate of metabolism for a certain 
drug can differ 1000-fold between phenotypes. Thus, the dosing required to achieve the 
same plasma levels of a drug metabolized mainly by CYP2D6, such as nortriptyline, differs 
10–20-fold among individuals. Despite this extensive variation in metabolic capacity among 
patients, dosing is, at present, principally population based (i.e. doses are based on the 
plasma levels of the drug obtained on average in the population at a certain dosage), but not 
individual based. 
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Box 1. Potential consequences of polymorphic drug metabolism. 
CYP polymorphisms affect the response of individuals to drugs in many ways (see Box 1.) 
and it alters the therapial regimen of many diseases such as depression, psychosis, cancer, 
cardiovascular disorders, ulcer and gastrointestinal disorders, pain and epilepsy and many 
others. The problem is that the use of genotyping or genomic methods to inform clinical 
decisions about drug response are not widely practiced (Varmus, 2010) but it would be 
necessary, expecially when drugs have narrow therapeutic indexes, when severe side effects 
occur or when the rate of non-responders is high. In resent years, the FDA has aggressively 
pursued drug-label modification when excess risk can be convincingly linked to a genetic 
marker. The FDA-mandated incorporation of pharmacogenomic information in drug 
labeling will remain an important step in the acceptance of pharmacogenomics in clinical 
practice (Wolf & Smith, 2000).  
In the next section, relevant therapeutic areas where CYP polymorphism significantly 
influences the response of drugs or the incidence of adverse drug reactions will be 
presented. 
2.1 Role of pharmacogenetics in therapies  
At the present time, decisions about which medications to prescribe are made on a trial and 
error basis for many disorders. Under the pharmacogenomic paradigm, genetically based 
screening methods would allow the tailoring of drug therapy, drug selection and dosing 
according to an individual's ability to metabolize a drug. There are many disorders where it 
is already taken into consideration and applying information about the patient's genetic 
makeup has high impact on therapeutic outcome.  
2.1.1 Cancer  
Oncology is a field that is already being revolutionized by pharmacogenomics. Cancer 
pharmacogenomics is complicated by the fact that two genomes ar involved: the germline 
genome of the patient and the somatic genome of the tumor.  Chemotherapeutic drugs are 
very sensitive to genetic background, since in general they are unspecific drugs with narrow 
therapeutic indexes that result frequent severe or even fatal toxicities. 
Germline genetic variations in cancer cells 
Tamoxifen. Tamoxifen is an estrogen receptor modulator used in hormone receptor positive 
breast cancers. It has been suggested that CYP2D6 activity is required for the formation of 
endoxifen the active metabolite of tamoxifen (Jin et al., 2005). There are several studies 
proving that CYP2D6 PMs have worsened relapse–free time and disease-free survival rate, 
but they do not experience hot flashes at the same magnitude as compared with patients 
carrying the wild type allele. A similar loss of effectiveness is obtained as a result of enzyme 
inhibition (by serotonin reuptake inhibitors, antidepressants and other CYP2D6 inhibitors). 
• Lack or extended pharmacological effect       ● Exacerbated drug-drug interactions 
• Drug toxicity     ● Drug resistance 
• Lack of prodrug activation   ● Adverse drug reactions 
• Increased effective dose    ● Idiosyncrasy 
• Metabolism by alternative pathways  ● Precarcinogen activation 
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Another CYP enzyme, CYP2C19 has been shown to metabolize tamoxifen to its active form. 
Carriers of CYP2C19*17 allele variants have been shown to exhibit a more favourable 
clinical outcome, since these patients activate tamoxifen in greater extent. This allele may be 
especially relevant for patients with low levels of CYP2D6 (Rodriguez-Antona et al., 2010). 
Cyclophosphamide. Cyclophosphamide (CPA), a prodrug used in cancer therapy and for 
treatment of some autoimmune disorders is activated to 4-hydroxycyclophosphamide by 
CYP2C19, CYP2C9, CYP3A4 and CYP2B6. It has been shown that carriers of CYP2C19*2 or 
CYP2B6*5 had a significant lower CPA elimination and worse therapeutical outcome. 
CYP2B6 enzyme expresses also in the liver and it metabolizes ifosfamide, tamoxifen, 
procarbazine and thiotepa in the same manner as it activate CPA (Takada et al., 2004; 
Rodriguez-Antona et al., 2010). 
Tegafur. Tegafur is also a prodrug which is activated to 5-fluorouracil by CYP2A6. Patients 
with CYP2A6*4 or CYP2A6*11 were poor metabolizer of this drug. Because other CYP 
enzymes influence the metabolism of tegafur (CYP3A4, CYP3A5, glutathione S-transferases) 
calculation of effective dose is difficult (Daigo et al., 2002). 
Thalidomide. Bioactivation of thalidomide is dependent on metabolism by CYP2C19 (5-
hydroxythalidomide). Another pathway producing arene oxid from thalidomide also egsists 
and it is mediated by CYP1A1 and CYP2E1. It was reported that in multiple myeloma, 
response to thalidomide and dexamethasone parallel treatment was higher in CYP2C19 EMs 
than in PMs. The lower response rate observed in PMs is possibly due to the reduced 
activity to inhibit angiogenesis. Despite these facts there is no big influence of CYP2C19 
polymorphism to treatment outcome (Vangsted et al., 2010).  
Somatic genetic variations in cancer cells 
CYP3A4 tumor expression could be somatically altered in specific tumors and it could be 
useful predictor for the effectiveness of drugs that are subject to CYP3A4 metabolism (for 
e.g. drug resistance in cancer tissue). Vincristine, CPA, etoposide treatments in lymphoma 
or docetaxel in breast cancer are all substrates of tumor CYP3A4 and their local metabolism 
could have therapeutical consequences due to their narrow therapeutical window. CYP2B1 
is also overexpressed in breast cancer and there are several therapeutic approaches focusing 
on higher CYP2B1 metabolism in tumor cells than in other body cells (Rodriguez Antona et 
al., 2010).  
2.1.2 Depression  
CYP2D6 and CYP2C19 metabolize virtually all of the antidepressants, many of which are 
also strong inhibitors of the enzyme.  
Antidepressants  
Tricyclic antidepressants (TCAs) are medications used to alleviate mood disorders, such as 
major depression dysthymia or anxiety disorders. CYP2D6 mediated metabolism of 
antidepressants leads to equally potent metabolites but the risk for side effects in poor 
metabolizers for CYP2D6 has been shown to be higher than in extensive metabolizers even 
if the sum of parent drug and metabolite was the same. Because of these adverse effects, in 
case of TCAs, there should be a dose adjustment depending on the patients genotype (for 
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e.g. single dose paroxetine is changing 10-fold in EMs compared to PMs) (Table 1.). 
Genotyping for CYP2D6 in psychiatric patients is widely accepted and is more or less the 
only pharmacogenetic test used in clinical practice (Kirchheiner et al., 2004). 
 
Drug Dosing Usual dose (mg) EM (%) IM (%) PM (%) 
CYP2D6-dependent 
Amitriptyline 
M 150 120 90 50 
S 50 120 80 70 
Nortriptyline 
M 150 120 90 50 
S 50 140 70 50 
Imipramine 
M 150 130 80 30 
S 50 110 100 60 
Paroxetine 
M 20 110 90 70 
S 20 130 70 20 
Venlafaxine M 150 130 80 20 
CYP2C19-dependent 
Amitryptiline M 150 110 80 60 
Imipramine 
M 150 100 80 60 
S 50 100 90 70 
Clomipramine S 50 100 90 70 
Table 1. M/S dosage recommendations of antidepressants for multiple-dosing or for 
beginning of treatment in relation to CYP2D6 and CYP2C19 polymorphism (M-maintenance 
treatment, S-single dose) (Kirchheiner et al., 2001). 
CYP2C19 polymorphism also influences the blood level of citalopram, amitriptyline and 
other antidepressants (Table 1.). Amitriptyline is demethylated to nortriptyline by CYP2C19 
which is further metabolised to nonactive metabolites. CYP2C19 polymorphism alone does 
not affect the therapeutic outcome, since nortriptyline the metabolite is an active 
antidepressant, but side effects are different if the amitriptyline/nortriptilline balance is 
changing. The highest risk for ADRs occur when a patient is EM for CYP2C19, but PM for 
CYP2D6, since CYP2C19 produces a high amount of nortriptyline, but there is no CYP2D6 
to metabolize it to inactive metabolites (Jornil et al., 2010). 
Serotonin reuptake inhibitors  
The pharmacokinetics of serotonin reuptake inhibitors (SSRIs) is complex, they are very 
lipid solible, high clearence drugs subjected to multiple metabolic pathways. 
Fluoxetine. Fluoxetine is metabolised to norfluoxetine, which is 20 times less potent SSRI 
than the original molecule. CYP2D6 is responsible for R-norfluoxitene production and 
CYP2C9 and CYP2D6 produces S-norfluoxetine (Fuller et al., 1992). CYP3A4 can also 
metabolise this drug, when CYP2D6 becomes saturated (Margolis et al., 2000). Although 
genetic polymorphism influence greatly the level of fluoxetine, it is hard to predict the gene-
concentration relationship because of several metabolic pathways. 
Paroxetine. This drug is inactivated by CYP2D6 (Bloomer et al., 1992). PMs for this enzyme 
tolerate much smaller dose than EMs (Table 1.). Single dose or multiple dosing makes 
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difference in paroxetine addministration, because with chronic dosing metabolism is 
saturable and autophenocopy could occur (Laine et al., 2001).  
2.1.3 Psychosis  
Antipsychotic drugs are widely prescribed for a multitude of psychiatric conditions. 
CYP2D6 metabolizes many psychotropic drugs, including antipsychotics like haloperidol, 
thioridazine, perphenazine, chlorpromazine, risperidone, and aripiprazole. 
Numerous authors suggested that genotyping for families of CYP enzymes (CYP2D6, 
CYP1A2) could potentially aid in prescribing antipsychotic drugs, since there are significant 
risks associated with their polymorphism, such as movement disorders (CYP1A2, CYP2D6), 
and cardiovascular adverse effects (CYP2D6) (Foster et al., 2007). CYP2D6 PMs had four 
time higher Parkinsonism like side-effects than EMs. Also, occurence of other ADRs in 
response to treatment increased from CYP2D6 EMs to PMs. Furtermore, the duration of 
treatment was higher in PM patients, which increased the costs about 4000-6000$ (Ingelman 
Sundberg, 2004b). 
2.1.4 Epilepsy  
Effective dosing of phenytoin is highly linked to CYP2C9 genotype. Patient cariing defective 
alleles show more frequently side effects for e.g. ataxia, diploidia and other neurological 
symptoms (Lee et al., 2002). Clobazam is also used in the treatment of epilepsy. This drug is 
metabolized to N-demethylclobazam, which is further processed by CYP2C19 to 4-
hydroxydesmethylclobazam. In CYP2C19 PM patients there is an accumulation of N-
demethylclobazam, which causes side effects such as drowsiness (Kosaki et al., 2004). 
Diazepam, another antiepileptic and anxiolitic is metabolized by CYP2C19 and CYP3A4. 
Both enzymes convert it to desmethyldiazepam. CYP2C19 produces two other metabolites 
also, oxazepam and temazepam (Andersson et al., 1994; Jung et al., 1997). PMs for CYP2C19 
enzyme metabolize slower this drug and took longer to emerge from anesthesia than for 
EMs (Inomata et al., 2005). Although diazepam has a clear gene-concentration effect, it is not 
predictable for the dose because of the many other active metabolites produced and 
involvement of other CYP enzymes. 
2.1.5 Pain  
Codeine. Codeine and tramadol needs to be metabolized to its active forms (morphine or o-
desmethyltramadol), before pain relieving effects are observed. Codeine is metabolised by 
CYP2D6 to its active metabolite, morphine, with CYP3A4 to norcodeine and with 
glucuronide transferase to codeine-6-glucuronide. CYP2D6 polymorphism affects greatly 
the precent ratio of these metabolites, which means that PMs do not bioactivate enough 
codeine to morphine and EMs are at risk of CNS depression and other side effects due to 
elevated morphine production (Table 2.) (Leppert, 2011).  
Gasche et al reported a patient who received oral codeine at daily dose of 75 mg and who 
experienced symptoms of morphine overdose (lack of consciusness, respiratory depression) 
after 4 days of treatment. The patient recovered after intravenous administration of naloxon. 
The cause of these sympthomes was his CYP2D6 EM phenotype as genotyping showed 3 or 
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more functional alleles. The patient was concomitatantly treated with claritromycin and 
voriconazole, both known inhibitors of CYP3A4 as confirmed by low CYP3A4 activity 
(Gasche et al., 2004) 
 
Effects of metabolised codeine EM PM 
Morphine conc. (% of codeine) 3.9% 0.17% 
Analgesia Yes No 
Pricking pain threshold Increased No effect 
Tolerance thresholds to heat and pressure Not altered Not altered 
Peak pain and disconfort during cold pressor test Reduced Not changed 
Adverse effects Yes Yes 
Table 2. Effects of codeine’s active metabolite, morphine in relation to different CYP2D6 
polymorphisms. 
Dihydrocodeine. Dihydrocodeine (DHC) is a semi-synthetic analogue of codeine and it is used 
as analgetic, antitussive drug or for treatment of opioid addiction. DHC is metabolised to 
dihydromorphine (DHM) mostly by CYP2D6 (DHM percentage of a single oral DHC dose; 
9%EM, 1% PM). Although DHM display greater affinity for opioid receptors than DHC, its 
pharmacological role in analgesic effect is not proven. Studies performed to date indicate 
that DHC analgesia is independent of CYP2D6 activity (Leppert, 2011). 
Tramadol. Tramadol is a very usfull pain relief medication in neonates and infants. It is 
primary metabolized into its more active metabolite, O-demethyl tramadol by CYP2D6. EMs 
for CYP2D6 enzyme react better to tramadol treatment, pain treshold tests showed better 
tolerance of pain, than in PMs. PMs need approximately 30% higher tramadol doses than 
those with extensive CYP2D6 activity (EMs) (Ingelman-Sundberg et al., 2007). 
2.1.6 Cardiovascular diseases  
Genetic variation influences the dose of many cardiovascular drugs, because most of them 
has narrow therapeutic indexes. Cardiovascular diseases are treated with many different 
classes of drugs, such as antianginals, antihypertensives, antiarrhythmics, anticoagulants, 
antiaggregating agents, lipid lowering drugs, etc. Many of these drugs are metabolized 
through the polymorphic CYP2D6, CYP2C9 and CYP2C19 enzymes. 
For example, the antianginal perhexiline metabolism is controlled by the polymorphic 
CYP2D6 enzyme. After perhexiline treatment a gene-dose effect has been observed; in poor 
metabolizers, perhexiline plasma concentrations can be very high (6-fold higher than in EMs 
after a single dose of perhexiline) which explains its hepatotoxic and neuropathic side 
effects. Determination of the ratio between perhexiline and its metabolite early in treatment 
may facilitate appropriate dose adjustment which may range from 10 mg in PMs to 500 mg 
in EMs (Cooper et al., 1984).   
Oral anticoagulants 
CYP2C9 and the C1 subunit of the vitamin K epoxide reductase (VKORC1) genotypes are 
associated with the variability in the overall pharmacodynamic responses to oral 
anticoagulants, such as warfarin, acenocoumarol and phenprocoumon. All three molecules 
have low therapeutic indexes and the dose required to produce a normal prothrombin time 
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is largely unpredictable. The consequences of under or over treating can be dire 
(thromboembolism or hemorrhage) (Gardiner & Begg, 2006). 
Warfarin. S-Warfarin is 3- to 5-fold more potent than R-warfarin and its responsible for 70% 
of the overall anticoagulant effect. S-warfarin is mostly metabolized by CYP2C9 and in 1-
1.5% by CYP4F2, whereas R-warfarin is metabolised by CYP3A4 and CYP1A2. Variations in 
genes central to warfarin activity (VKORC1, vitamin K reductase regulator (CALU) and 
gamma glutaryl carboxilase (GGCX)) are also polymorphic and they have to be taken into 
consideration during dose calculation (Table 3.).  
 
Gene Allele Outcome 
VKORC1 3673;G-1639A GG (insensitive), GA (sensitive), AA (most sensitive) 
GGCX C>G 
CC (less sensitve), CG (more sensitive), GG (most 
sensitive) 
CALU 11G>A;R4Q 
GG (less sensitive), GA (more sensitive), AA (most 
sensitive) 
CYP4F2 C>T; V433M CC (most sensitive), CT (more sensitive),TT (less sensitive) 
CYP2C9 
CYP2C9*2 ;R144C 
CYP2C9*3 ;I359L 
CYP2C9*5 
CYP2C9*6 
CC (*1/*1, wild type), CT (*1/*2, IM), TT (*2/*2, PM) 
AA (wild type), AC (-/*3, PM), CC(*3/*3, PM) 
CC (wild type), CG (-/*5, PM), GG (*5/*5, PM) 
AA (wild type), A-(-/*6, PM), --(*6/*6, PM) 
Table 3. Genes and their alleles that affect warfarin therapy. Various CYP alleles are just 
examples. The complete list could be found on the following homepage: 
http://www.cypalleles.ki.se.  
Two common CYP2C9 allozymes have only a fraction of the level of enzyme activity of the 
wild type allozyme CYP2C9*1: 12% for CYP2C9*2 and 5% for CYP2C9*3. Since VKORC1, 
CALU and GGCX genotype together with CYP2C9 and CYP4F2 genotype and factors such 
as age, body size may account just for 50-60% of the variability in warfarin dosing 
requirements, prothrombin time monitoring is still necessary during dose adjustment. But 
still, genotypization is recommended because of risk of side effects caused by the 
pharmacodinamic properties of warfarin (strong gene-dose relationship, strong dose-effect 
relationship and low therapeutic index). In 2010 the FDA revised the label on warfarin 
providing genotype-specific ranges of doses and suggesting that genotypes should be taken 
into consideration when the drug is prescribed (Wang et al., 2011; Takahashi et al., 1998). 
Acenocoumarol. This drug is used in preference to warfarin in some countries, expecially in 
Europe. R-Acenocoumarol is metabolized by several enzymes and produces most of the 
effect. S-Acenocoumarol is metabolized almost exclusively by CYP2C9 and although active, 
it contributes comperativly little because of its fast metabolism. The presence of one 
CYP2C9*3 allele (PM)  is associated with 20-30% lower acenocoumarol doses compared with 
wild type, whereas two alleles lead to very low dose requirements (1 mg/day instead of 2.5 
mg/day) (Spreafico et al., 2002; Gardiner et al., 2006). 
Phenprocoumaron. Phenprocoumaron exist as R and S-enantiomer and CYP2C9 is responsible 
for the elimination of the S form. This anticoagulant undergoes a large proportion of 
elimination via alternative pathways (e.g. renal and CYP3A4), so any relationship with the 
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CYP2C9 genotype may be less important than for warfarin or acenocoumarol (Toon et al., 
1985).  
Antiplatelet agents 
Clopidogrel. Clopidogrel is an antiplatelet and it inhibits adenosine diphosphate (ADP)-
stimulated platelet activation by binding irreversibily to a specific platelet receptor of ADP, 
P2Y 12, thus inhibiting platelet aggregation.  
Absorption of clopidogrel in the gut is opposed by the efflux pump P-glycoprotein, encoded 
by the ABCB1 gene. Once absorbed, approximately 85% of the drug is converted to an 
inactive metabolite by the action of esterases. The remaining 15% must undergo a two-step 
transformation process to become active. The first step produces 2-oxo-clopidogrel and is 
catalyzed in varying proportions by the cytochromes CYP2C19, CYP1A2 and CYP2B6. The 
second step, which produces the reactive metabolite, can be catalyzed by CYP3A4/5, 
CYP2B6, CYP2C19 or CYP2C9. Among so many enzymes only genetic variation in CYP2C19 
and ABCB1 are associated with clopidogrel efficacy.  As compared with subjects with no 
CYP2C19 variant allele, subjects carrying one or two CYP2C19 loss-of-function alleles have 
been shown to have lower plasma concentrations of the active metabolite of clopidogrel and 
a decrease in the antiplatelet effect of clopidogrel and an increased likelihood of 
cardiovascular event. In 2010, the FDA added a boxed warning to prescribing information 
for clopidogrel, stating that persons with a CYP2C19 variant encoding a form of the enzyme 
associated with a low rate of metabolism might require dose adjustment or the use of a 
different drug (Simon et al., 2009; Ingelman-Sundberg et al., 2007). 
Antiarrhythmics   
Antiarrhythmia drugs are used to treat abnormal heart rhythms resulting from irregular 
electrical activity of the heart. Most antiarrhythmics are metabolized via CYP3A or CYP2D6 
(Gardner et al., 2006). 
Propafenone. Its ennatiomers have equal sodium channel blocking activity, but S-
propafenone is 100-fold more potent as a β-blocker (Kroemer et al., 1989a). Propafenone is 
metabolised via CYP2D6 to 5-hydroxipropafenone, which has sodium channel blocking 
activity similar to that of the racemic parent drug but less ß-blockade and also by CYP1A2 
and CYP3A4 to N-desalkylpropafenone (Kroemer at al., 1989b). Propafenone inhibits 
CYP2D6 strongly, with 70% phenocopying and R-propafenone inhibits the metabolism of 
the S-enantiomer. CYP2D6 status is generally thought to matter little for antiarrhythmic 
effect, but more for β-blockade and for side effects in central nervous system. Because of non 
linear pharmacokinetic and problems with active metabolites, enantiomers and 
phenocopying, it is hard to translate the proven gene-concentration ratio to clinically 
effective dose (Siddoway et al., 1987). 
Flecainide. Flecainide is inactivated by renal elimination and in the liver by CYP2D6. Since 
the gene-effect relationships between CYP2D6 and flecainide seem minor, there is no need 
for clinical monitoring of this drug (Mikus et al., 1989). 
Mexiletine. Mexiletine is a chiral, with the R-enantiomer having greater activity. It is 
metabolized to various metabolites by CYP2D6 and other enzymes. Due to CYP2D6, a 
minor gene-concentration effect seems to be present, but because of other elimination 
pathways it is not predictable for the dose (Labbe & Turgeon, 1999). 
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β-blockers  
Beta-blockers reduce the effects of the sympathetic nervous system on the cardiovascular 
system. These drugs are effective against high blood pressure, congestive heart failure, 
abnormal heart rhythms or chest pain. Their pharmacokinetic is very diverse; those which 
are metabolised by polymorph CYP enzymes are carvedilol, metoprolol, propranolol and 
timolol. 
Carvedilol. Beside other metabolic pathways, CYP2D6 metabolizes carvediol to its more 
potent ß-blocker metabolite 4-hydroxyphenylcarvedilol. Polymorphism of CYP2D6 does not 
affect significantly the overall effect of this drug (Oldham & Clark, 1997). 
Metoprolol. Metoprolol is a ß1-selective blocker and is given as a racemate. Beside other 
pathways, metoprolol is under the control of CYP2D6. Metoprolol seems to have both 
consistent gene-concentration and gene-effect relationships in healthy volunteers, 
suggesting that dose reduction to 25% should occur in PMs or those phenocopied by other 
drugs (McGourty et al., 1985a).  
Propranolol. Propranolol is metabolsed by CYP2D6, but CYP2D6 polymorphism contributes 
little to variation in plasma concentration of this drug (Lennard et al., 1984). 
Timolol. Timolol is a non selective ß-blocker and is metabolised mainly by CYP2D6. 
Although the ß-blocking effect can occur with very low level of the drug, it is not necessary 
to genotype before determinating the dose of the drug (McGourty et al., 1985b). 
Angiotensin II Blockers 
CYP2C9 metabolizes several antihypertensive angiotensin II receptor antagonists, such as 
losartan, irbesartan, candesartan or valsartan. Although losartan and candesartan are 
activated, irbesartan is metabolised by CYP2C9, there is no need for genotyping of the 
enzyme variants during the treatment (Gardiner et al., 2006). 
2.1.7 Metabolic disorders  
Oral antidiabetics 
CYP2C9 is the main enzyme catalyzing the biotransformation of sulphanylureas such as 
tolbutamide, glyburine, glimeprimide and glipizide. The total oral clearence of 
sulphanylureas has been shown to be 20% in PM persons of that in wild type, whereas the 
clearence in heterozygous carriers was between 50% and 80% of that of wild type genotype. 
Therefore, adverse effects of many oral antidiabetics may be reduced by CYP2C9 genotype-
based dose adjustments (Gardiner et al., 2006). 
2.1.8 Gastrointestinal disorders  
Protone pump inhibitors 
The PPIs undergo extensive hepatic biotransformation by the CYP system. The principal 
isoenzymes involved in the metabolism of the PPIs are CYP2C19 and CYP3A4 (Andersson 
et al., 1998; Pierce et al., 1996). CYP2C19 is the main enzyme involved in the metabolism of 
PPIs omeprazole, pantoprazole and lansoprazole and the CYP2C19 genotype is a strong 
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determinant of the acid inhibitory effect of these drugs. Higher doses of the PPIs should be 
used in homozygous EMs (e.g. 40 mg), and lower doses could be used in heterozygous EMs 
and PMs (e.g. 10 mg).  
 
Eradication therapy 
Eradication rate 
(%) 
Av.  
cure rate 
(%) EM IM PM 
Dual 
therapy 
Omeprazole/Amoxicillin 
20 mg 1x/500mg/two weeks 4x daily 
30 60 100 63 
Omeprazole/Amoxicillin 
40 mg 1x/2000mg/one week 4x daily 
33 30 100 54 
Rabeprazole/Amoxicillin 
10 mg 2x/500mg/two weeks 3x daily 
60 92,2 92 80 
Triple 
therapy 
Omeprazole/Amoxicillin/Clarithromycin 
40 mg 1x/1500mg/600 mg/one week 4x daily 
81 94,5 100 92 
Table 4. Dual and triple eradication therapy for H. pylori infection in relation to different 
CYP2C19 polymorphisms (Aoyama et al., 1999; Furuta et al., 2005). 
Genotyping is also important in Helicobacter pylori eradication (Table 4.). If patients are 
confirmed as being PMs, dual therapy with PPI plus amoxicillin may be appropriate, as the 
eradication rate is likely to be high (>90%). This regimen has the advantage of being cheaper 
and less complex than triple therapy regimens. Individuals identified as homozygous EMs 
might be better to commence a triple drug regimen (PPI, amoxicillin and clarithromycin). 
2.1.9 Infection  
Antiretrovirals 
Efavirenz. Efavirenz, a nonnucleoside reverse transcriptase inhibitor is an initial therapy 
during HIV infections. This drug is metabolised by CYP2B6 enzyme. In PMs for CYP2B6, 
efavirenz has been shown to be responsible for central nervous system side effects (sleep or 
mood disorders) and they also have increased risk for drug resistance (Rotger et al., 2005). 
Nelfinavir. The protease inhibitor nelfinavir is metabolized mainly to nelfinavir hydroxy-t-
butylamide by CYP2C9, which exhibits potent antiviral activity, and to other minor 
products by other CYPs that are inactive (Hirani et al., 2004). CYP2C9 polymorphism 
appears to have a clinical effect on nelfinovir, but the exact extent of the impact awaits 
additional clinical studies and confirmation. Nelfinavir is an inhibitor of CYP3A. 
Coadministration of nelfinavir and drugs primarily metabolized by CYP3A may result in 
increased plasma concentrations of the other drug that could increase or prolong both their 
therapeutic and adverse effects (Niemi et al., 2003; Fulco et al., 2008). 
2.1.10 Rheumatoid arthritis 
Nonsteroid antiinflamatory drugs (NSAID) are commonly used for rheumatoid arthritis 
treatment and many of them are metabolised by the CYP2C9 enzyme. The low activity 
alleles of CYP2C9 (CYP2C9*2, CYP2C9*3) has been shown to influence the pharmacokinetics 
of ibuprofen, naproxen, diclofenac and celecoxib (Kircheiner & Brockmoller, 2005). From 
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these drugs, celexocib and ibuprofen have extensive CYP2C9 metabolism (Kircheiner et al., 
2002; Lundblad et al., 2006). In PM patients for CYP2C9 these two drugs have 2-7 fold longer 
effects and stronger gastrointestinal side effects (Martin et al., 2001).  
3. Pharmacoepigenetics  
Much of the interindividual variation in drug response has been addressed by 
pharmacogenetics and it is imperative for clinicians to consider during determination drug 
efficacy and reducing side effects. But it is important to note that many inherited and 
acquired discrepancies cannot be resolved only by sequencing the whole genome and 
identifying genetic variations, there are other heritable factors affecting the activity of a gene 
such as covalent modification of DNA and histones, DNA packaging around nucleosomes, 
chromatin folding and attachment to the nuclear matrix or miRNA regulation. These 
changes together are called epigenetic changes and with true genetics they show how genes 
might interact with their surroundings to produce a phenotype. It means that beside genetic 
information, epigenetic factors have to be also taken into consideration during 
determinating variation in drug response. Beside individual variations, there could be a 
pharmacoepigenetic basis for other drug related effects, such as drug resistance (for e.g. 
doxorubicin resistance due to epigenetic regulation of ABCG2 transporter in cancer cells) 
(Calgano et al., 2008).  
In the following section, an overview has been provided of new results in the field related to 
regulation by DNA methylation, histone modulation and miRNA, since they are topics of 
considerable current interest which may describe the large variation in expression seen for 
several important CYPs (Okino et al., 2006; Antilla et al., 2003; Dannenberg et al., 2006; 
Tamási et al., 2011). 
3.1 Epigenetic regulation  
DNA methylation. DNA methylation occurs predominantly at CpG sites in the mammalian 
genome by the DNA methyltransferase (DNMT) enzymes. The majority of CpG pairs are 
chemically modified by the covalent attachment of a methyl group to the C5 position of the 
cytosine ring (Tate & Bird, 1993; Calcagno et al., 2008). Methylation of DNA is regarded as a 
means of regulating gene expression through two general mechanisms. First, DNA 
methylation of gene promoters may prevent the physical binding of some transcription 
factors to their DNA binding sites (Rountree et al., 2001). Second, the transcriptional 
silencing capability of DNA methylation may occur via indirect mechanisms involving 
changes in chromatin conformation. There is extensive evidence to support a functional role 
for promoter-CGI methylation in transcriptional repression (Weber et al., 2007; De Smet et 
al., 1999; Stein et al., 1982).  DNA methylation of CpG-rich promoters of some genes 
correlates with tissue specific gene silencing (Futcher et al., 2002; Song et al., 2005). To date, 
several studies show altered DNA methylation of CYPs what could have importance in 
drug and endogen compound metabolism.  
Histone modification. Posttranslational modifications such as phosphorylation, acetylation, 
methylation and ubiquitination on the N-termini of histones have been shown to play 
critical roles in gene regulation (Kouzarides, 2007). It is believed that the combination of 
modifications of the chromatin-associated histone and non-histone proteins, and the 
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interplay between these modifications create a marking system (“histone code”), which is 
responsible for compact DNA (heterochromatin) or more opened, transcriptionally active 
(euchromatin) configuration, that allows transcription (Jenuwein & Allis, 2001).  
miRNA regulation. miRNAs, another part of the epigenetic machinery, are single-stranded 
RNA molecules of 21-24 nucleotides in lenght that arise from miRNA genes, which when 
transcribed, can promote posttranscriptional regulation by binding to 3’-untranslated 
regions (3’UTRs) of target mRNAs promoting their degradation and cleavage as 
miRNA/RISC complex (RISC-RNA Induced Silencing Complex) or interfering with their 
translation. Besides their direct influence on mRNA transcription, some miRNAs, defined as 
epi-miRNAs, have an indirect impact on gene transcription by affecting the epigenetic 
machinery, including DNA methyltransferases, histone deacetylases and other mechanisms 
(Fabbri et al., 2010). Post-transcriptional regulation by miRNA could be responsible for a 
portion of the significant amount of unexplained interindividual variability in CYP enzyme 
expression and activity. 
The modified histones, methylated DNA sequences and miRNAs may interact in a 
synergistic manner, including methyl-CpG binding protein, nuclear receptor corepressor 
(NCoR), associated histone deacetylases, histone methyl transferases and epi-miRNAs to 
regulate gene expression (Yoon et al., 2003). The mentioned epigenetic changes affect the 
expression of drug metabolizing enzymes and with that ultimately affect the 
pharmacokinetic or pharmacodinamic properties of a drug. 
3.2 Epigenetic regulation of P450s  
CYP1A1: CYP1A1 is mainly involved in the metabolic activation of polycyclic aromatic 
hydrocarbons, which are common enviromental pollutants. Important functional 
polymorphisms have been not described with this gene, but still there are several epigenetic 
processes which regulate CYP1A1.  
Both hypermethylation (less active CYP1A1, slower metabolism of drugs) and 
hypomethylation (more active enzyme, higher metabolic rate) of CYP1A1 is described, 
mostly in cancer tissue. In prostate cells, CpG islands in CYP1A1 show segmented/selective 
methylation patterns: CpG sites from 1 to 36 are not methylated; this DNA region contains 
the CYP1A1 promoter and is responsible for correct initiation of gene transcription; CpG 
sites 37 to 90, which corresponds to the CYP1A1 enhancer region that mediates TCDD 
(2,3,7,8-Tetrachlorodibenzodioxin) inducibility, exhibits cancer cell-dependent 
hypermethylation and CpG sites 91 to 125 are commonly methylated, but known regulatory 
function has been not associated with this DNA region (Okino et al., 2006). Environmental 
factors, such as tobacco smoke have been shown to influence the DNA methylation of 
CYP1A1; smokers DNA were hypomethylated compared to non-smokers on the upstream 
regions, containing functional XREs. In addition, there was an inverse correlation between 
methylation and the number of cigarettes smoked daily. Cessation of smoking results in the 
methylation of CYP1A1 promoter being increased at 1–7 days after the last cigarette (Antilla 
et al., 2003). Although there was no correlation between ethoxyresorufin-O-deethylase 
(EROD) activity and the percentage of methylated DNA in a sample either in smokers or in 
nonsmokers, decrease in methylation caused significant higher CYP1A1 activity. A high 
inducibility of CYP1A1 has been connected with increased susceptibility to smoking-
associated lung cancer (Kellermann et al., 1973; Stücker et al., 2000). 
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Chromatin structure has been suggested to play an essential role in CYP1A1 transcription 
(Table 5). In the basal state, histone deacetylase 1 (HDAC1) is bound to the CYP1A1 
promoter and is released in concert with the recruitment of p300 upon benz[a]pirene (B[a]P) 
ligand activation of the AHR. HDAC1 removal allows for several histone modification steps 
associated with the AHR-mediated induction of CYP1A1 expression. Removal of HDAC1 is 
necessary, but not sufficient to activate CYP1A1 expression (Schnekenburger et al., 2007). 
miRNA regulation of CYP1A1 is also known. miRNA regulation by miRNA-18b and 
miRNA-20b of CYP1A1 was described by Wang and coworkers and a significant correlation 
was found between the mentioned miRNAs and CYP1A1 expression (Wang et al., 2009). 
 
 Methylation Histon modification miRNA 
 CpG region 
Compound/
disease 
Modification 
Compound/ 
disease 
miRNA Tissue/ cell 
C
Y
P
1
A
1
 
Enchancer/ 
promoter 
Cancer, 
tobacco smoke
Acetylation B[a]P 
Hsa-miR-18b, 
Hsa-miR-20b 
Transformed 
lymphocytes 
C
Y
P
1
B
1
 
Enchancer/ 
promoter 
Cancer - - 
Hsa-miR-27b Cancer 
Hsa-miR-124 Brain 
C
Y
P
2
E
1
 
Region not 
described 
Ethanol - - Hsa-miR-378 HEK293 
C
Y
P2
W
1 I.exon/  
I.intron 
Cancer - - - - 
C
Y
P
3
A
 
Enchancer/ 
promoter 
Cancer Methylation Rifampicin 
Hsa-miR-27b HEK293 
Hsa-miR-148a Liver 
Table 5. Epigenetic regulation of drug metabolism related P450s (“-“ no data). 
CYP1B1: CYP1B1 activates various procarcinogens, metabolizes the antiestrogen 
tammoxifen, some flavonoids or benzpyrene derivatives. This enzyme is overexpressed in a 
variety of human tumor cells such as lung, breast, liver, gastrointestinal tract, and ovarian 
cancer (Murray et al., 1997).  CYP1B1 may be an important tumor marker, because it 
hydroxylates estrogenes and activates many procarcinogenes. CYP1B1 enzyme could be 
methylated both on the promoter and on the enchancer of the gene. Promoter region 
contains the CpG sites of the core promoter region including SP1 binding sites and the 
enhancer region including AHR/ARNT (ARNT-Aromatic Hydrocarbone Receptor Nuclear 
Translocator) binding sites DRE2 and DRE3. Aberrant methylation in the CYP1B1 gene 
affects binding of transcription factors and enchancer molecules. Because expression of 
CYP1B1 is regulated by the methylation of its promoter/enhancer, this region may be a 
useful target for anticancer drugs and in preventive medicine (Tokizone et al., 2005). 
Human CYP1B1, which is highly expressed in estrogen target tissues, catalyzes the 4-
hydroxylation of 17-beta-estradiol. Tsuchiya and coworkers found an abundant amount of 
CYP1B1 protein in breast cancerous tissue and they identified a near-perfect matching 
sequence with miR-27b in the 3’-untranslated region of human CYP1B1. Human CYP1B1 is 
post-transcriptionally regulated by miR-27b (Tsuchya et al., 2006). Another brain-specific 
miRNA, miR-124, also downregulates CYP1B1 directly and modulate all AHR target genes 
indirectly by binding to AHR receptor (Lim et al., 2005). 
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CYP2E1: CYP2E1 is involved in the metabolism of various drugs, such as halothane, enflurane, 
theophylline or isoniazid. Methylation of the CYP2E1 gene inhibits the expression of this 
enzyme in prenatal period (Vieira et al., 1998). In adult tissues the methylation pattern of 
CYP2E1 gene differs among various tissue types such as lung, kidney, placenta, liver and skin 
indicating that DNA methylation results in tissue-specific regulation (Vieira et al., 1996). 
CYP2E1 is metabolizing ethanol to its carcinogenic metabolite acetaldehyde. Even small doses 
of ethanol are able to change the methylation pattern of CYP2E1 and with that, increase its 
transcription. Higher CYP2E1 activity could have importance in cancerogenesis, since CYP2E1 
is involved in bioactivation of other small-molecule precarcinogenes (Ghanayem et al., 2007). 
Mohri and coworkers recently found that miR-378 is involved in the post-transcriptional 
regulation of CYP2E1. The overexpression of miR-378 significantly decreased CYP2E1 
protein levels and enzyme activity in the cells expressing CYP2E1, including 3’-UTR, but not 
in the cells expressing CYP2E1 without 3’-UTR, indicating that the 3’-UTR plays a role in the 
miR-378-dependent repression (Mohri et al., 2010). Chronically induced CYP2E1 with 
ethanol or other CYP2E1 inducers is a high-risk factor for esophageal and gastrointestinal 
cancers, which gives importance to investigate transcriptional and post-transcriptional 
CYP2E1 regulatory mechanisms, as basic targets in anticancer therapy. 
CYP2W1: This enzyme has been shown to metabolise arachidonic acid and benzfetamine, as 
well as being able to metabolically activate several procarcinogens, including polycyclic 
aromatic hydrocarbon dihydrodiols, aflatoxin B1 or sterigmatocystin. CYP2W1 is expressed 
at relatively low levels (mRNA) in the human adult non-transformed tissues whereas the 
expression in colorectal cancer tissues was significantly higher (both at mRNA and protein 
levels) (Li et al., 2009; Edler et al., 2009). CYP2W1 gene expression appears to be governed 
by gene methylation. The CYP2W1 gene was shown to contain one functional CpG island in 
the exon 1-intron 1 region which was methylated in cell lines lacking CYP2W1 expression, 
but unmethylated in cells expressing CYP2W1 (Karlgren et al., 2007; Gomez et al., 2007). 
CYP3A: These enzymes metabolise almost 50% of currently used drugs as well as 
endogenous and exogenous corticosteroids. Although CYP3A enzymes are not polymorph 
enzymes interindividual variability is high due to epigenetic regulatory mechanisms.  
Different DNA methylation pattern was found between primary hepatocytes and 
hepatocyte cell lines. HepG2 cells exhibit many cellular features of normal human 
hepatocytes, but also display characteristics resembling those of a cancerous or fetal 
hepatocyte. CYP3A expression in untreated HepG2 cells is fairly low, suggesting that their 
expression is reduced in these partially dedifferentiated cells. Dannenberg and coworkers 
were interested in determining whether CYP3A genes are regulated by DNA methylation in 
HepG2 cells. Their microarray experiments showed that after 5-aza-dC treatment (5-aza-2'-
deoxycytidine, methylation inhibitor), expression of CYP3A4, CYP3A5 and CYP3A7 was 2-
4-fold higher, suggesting the regulatory role of methylation with these CYPs (Dannenberg & 
Edenberg, 2006). Since CYP3A enzymes catalyse the transformation of many drugs, 
understanding their regulation would explain interindividual differences in drug response 
and would help to develop better personalized medicine. 
CYP3A4 transcription is also regulated by a histone methyltransferase enzyme called 
protein arginine methyltransferase 1 (PRMT1). PRMT1 is required for the transcriptional 
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activity of CYP3A4 by pregnane X receptor (PXR). It is recruited to 5'-region of the CYP3A4 
gene to methylate histone H4 as a response to the PXR agonist rifampicin (Xie et al., 2009).  
CYP3A4 is also regulated by constitutive androstane receptor (CAR) albeit it at a lower rate 
of expression. Assenat and coworkers reported that the synthetic glucocorticoid, 
dexamethasone, induces histone H4 acetylation at the proximal CAR promoter region, and 
indirectly affects CYP3A4 induction by regulating CAR expression (Assenat et al., 2004).  
Until now, one miRNA, miR-27b, has been described to regulate CYP3A4 expression by 
binding to the miRNA response element (MRE) within the 3’UTR region of CYP3A4 mRNA 
(Pan et al., 2009). Some miRNAs, such as miR-148a, which is selectively and abundantly 
expressed in the liver, regulates other liver specific genes, for e.g., the human PXR. miR-148a 
binds to the 3’-UTR region of PXR mRNA, thereby decreasing synthesis of PXR protein. 
Since CYP3A4 is a target for PXR, miR-148a indirectly modulates the inducible and/or 
constitutive levels of CYP3A4 expression (Takagi et al., 2008). Another example of indirect 
modulation would be the vitamine D receptor (VDR). VDR also regulates CYP3A4 and VDR 
could be down-regulated with miR-27b (Mohri et al., 2010). 
4. Conclusion  
Pharmacogenetics and pharmacoepigenetics is a scientific field which understands the role 
of an individual’s genetic background in how well a medicine works, and also what side 
effects occur during drug administration. The development of pharmacogenetics/ 
pharmacoepigenetics (for benefits and limitations see Box 2.) provides at least one 
mechanism for taking prescription away from its current empiricism and progressing 
towards more “individualised” drug treatment.  
 
 
Box 2. Potential benefits and limitations of pharmacogenetics/pharmacoepigenetics. 
The clinical applicability of pharmacogenetic testing depends on the relative importance of 
each polymorphism in determining therapeutic outcome. Doctors need to be aware of 
whether a drug they are prescribing is subject to pharmacogenetic variability and they have 
to know how to use this knowledge. Routine genotyping or phenotyping before drug 
administration can be made for very few drugs today and we are still a long way from 
having a pharmacogenetic DNA chip that general practitioners can use to identify all the 
drugs to which any particular patient is sensitive. There are many issues against testing, 
Benefits: 
• Development of drugs based on a patient’s genetic/epigenetic profile will maximise 
therapeutic effects, but decrease ADRs and other toxic effects 
• More precise dose is calculated, if beside other factors, genetic background also counts 
• Revival of older drugs with retrospective studies 
Limitations: 
• Identification of genes that may influence drug metabolism is very difficult, since more 
genes are involved in how someone reacts to a drug and these changes are small  
• The interactions with other drugs or environmental factors need to be determined 
before any conclusions are made about the genetic influence on how the drug is 
working 
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including specific factors that contaminate the signal, such as active 
metabolites/enantiomers, access and availability of the tests, complication for patients etc.  
What have been changed as a result of pharmacogenetic knowledge until today is the drug-
label modifications. There are more and more drug-labels where the pharmacogenetic 
consequence is highlighted (Table 6.). Drug labels may contain information on genomic 
biomarkers and can describe: drug exposure and clinical response variability, risk for 
adverse events, genotype-specific dosing, mechanisms of drug action, polymorphic drug 
target, disposition genes etc.  
 
CYP enzymes 
FDA-approved drugs with pharmacogenomic information in their 
labels 
CYP2C9 
Clopidogrel, Diazepam, Dextansoprazole, Drospirenone and Ethenyl 
Estradiol, Esomeprazole, Nelfinavir, Rabeprazole, Voriconazole 
CYP2C19 Celexocib, Warfarin 
CYP2D6 
Aripiprazole, Atomoxetine, Carvedilol, Cevimeline, Clozapine, Codeine, 
Dextromethorphan and Quinidine, Doxepin, Fluoxetine, Fluoxetine and 
Olanzapine, Metoprolol, Propafenone, Propranolol, Protryptiline, 
Quinidine, Risperidone, Terbinafine, Tetrabenazine, Thioridazine, 
Timolol, Tiotropium, Tolterodine, 
Tramadol and Acetaminophen,Venlafaxine 
Table 6. FDA-approved drugs with P450-related pharmacogenomic information in their 
labels (Taken from www.fda.gov, updated 2011, July).  
Another result of pharmacogenetic knowledge is including pharmacogenomics into clinical 
trials. Carlquist and Anderson reported that this year until May, a total of 158 
pharmacogenomic clinical trials were listed at http://www.clinicaltrials.gov. Of those trials 
the three leading disease areas for which pharmacogenetic guided intervention is sought 
were cancer (37%), psychiatric disorders (13%), and anticoagulation/thrombosis (9%) 
(Carlquist & Anderson, 2011). 
In addition to pharmacogenetics, it has been also predicted that DNA methylation, histone 
modification and RNA-mediated regulation also affects gene expression. Until now, cancer 
is the only disease, where pharmacoepigenetics of drug metabolizing enzymes seems to be 
important. Epigenetic changes influence sensitivity to chemotherapeutic drugs suggesting 
that epigenetic factors could serve as molecular markers predicting the responsiveness of 
tumors and other diseases to therapy.  
Ultimately, it could be concluded that pharmacogenetics and pharmacoepigenetics explains 
in large extent individual variation of drug metabolising enzymes and hopefully these two 
factors together will help to work out more specific dosing protocols for drugs. 
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